CMMB (Chemomab Therapeutics) 6-Month Price Index : 0.71 (As of Apr. 22, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2025-04-22), Chemomab Therapeutics's 6-Month Price Index is 0.71.

Competitive Comparison of Chemomab Therapeutics's 6-Month Price Index

For the Biotechnology subindustry, Chemomab Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics (NAS:CMMB) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics (NAS:CMMB) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Chemomab Therapeutics 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

2QV0:Germany 2QV0:Germany

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Executives

Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor	director, 10 percent owner, officer: Chief Executive Officer	15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen	director	C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel	officer: Chief Medical Officer	672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley	director	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles	director	5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin	officer: Executive VP, CFO & COO	2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost	director, officer: Chief Executive Officer	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish	director	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel	10 percent owner	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal	officer: Chief Financial Officer	16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon	officer: Chief Medical Officer	12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629